Featured Firms
Presented by BigVoodoo
Can a generic drug maker be held liable for failure-to-warn claims because its version of a popular drug gained FDA recognition as the industry standard? Not according to a ruling last week by a federal judge in Atlanta, who ruled that labeling claims against Mylan over its version of an anti-seizure drug were preempted under the Supreme Court's Pliva v. Mensing decision.
January 10, 2012 at 12:00 AM
1 minute read
Presented by BigVoodoo
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Honoring outstanding legal achievements focused at the national level, largely around Big Law and in-house departments.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS